Table 1.
Different panel for the detection of Homologous recombination repair (HRR) genes and homologous recombination deficiency (HRD) including loss of heterozygosity (LOH), telomeric allelic imbalance (TAI) and large scale state transitions (LST). Definitions of LOH, TAI and LST can be found in Section 3.3.
| Panel | Provider | Applicable in Lab | Focus | Number of Genes | LOH | TAI | LST |
|---|---|---|---|---|---|---|---|
| BROCA Cancer Risk Panel | UW Medical Center Laboratory Medicine—Genetics Lab |
no | Hereditary cancer predisposition syndromes/Ovarian cancer/Breast cancer | 74 | no | no | no |
| BRCANextTM | AmbryGenetics | no | Hereditary Gynecological carcinomas and/or Breast cancer | 18 | no | no | no |
| BRCANext-Expanded™ | AmbryGenetics | no | Hereditary Gynecological carcinomas and/or Breast cancer | 23 | no | no | no |
| CAN02 | CeGaT | no | Ovarian cancer/Breast cancer | 13 | no | no | no |
| CAN21 | CeGaT | no | Ovarian cancer/Breast cancer | 41 | no | no | no |
| Myriad myRisk® Hereditary Cancer | Myriad | no | Hereditary cancer predisposition syndromes/Ovarian cancer/Breast cancer | 36 | no | no | no |
| Myriad’s myChoice® CDx | Myriad | no | homologous recombination deficiency score/BRCA1,2 | 2 | yes | yes | yes |
| Oncomine BRCA Expanded Panel | Thermo Fisher Scientific | Yes | Ovarian cancer/Breast cancer and Prostate carcinomas | 15 | no | no | no |
| Oncomine HRR Pathway Predesigned Panel | Thermo Fisher Scientific | Yes | Homologous recombination repair genes and other | 28 | no | no | no |
| Oncomine Comprehensive Plus | Thermo Fisher Scientific | Yes | Pan-Cancer | 500+ | yes | no | no |
| Trusight Tumor 170 | Illumina | Yes | Pan-Cancer | 170 | no | no | no |
| TrueSight Oncology 500 | Illumina | Yes | Pan-Cancer | 500+ | no | no | no |
| CentoBreast® | Centogene | no | Ovarian cancer/Breast cancer | 30 | no | no | no |
| CentoCancer® | Centogene | no | Pan-Cancer | 70 | no | no | no |
| HANDLE HRR NGS Panel | AmoyDx | yes | Homologous recombination repair genes and other | 32 | no | no | no |
| HRD Focus Panel | AmoyDx | yes | homologous recombination deficiency score/BRCA1,2 | 2 | yes | yes | yes |
| Invitae Common Hereditary Cancers Panel | Invitae | Yes | Hereditary cancer predisposition syndromes/Ovarian cancer/Breast cancer | 47 | |||
| FoundationOne®CD | Foundation Medicine | no | Pan-Cancer | 324 | |||
| FoundationFocus CDxBRCA LOH | Foundation Medicine | no | 2 | yes | no | no | |
| NeoTYPE® HRD+ Profile | NeoGenomics | no | homologous recombination deficiency/Homologous recombination repair genes | 30 | no | no | no |
| QIAseq Homologous Recombination Repair (HRR) Panel | Qiagen | yes | Homologous recombination repair genes | 15 | no | no | no |
| SureMASTR HRR | Agilent | yes | Homologous recombination repair genes | 17 | no | no | no |